Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic.

Slides:



Advertisements
Similar presentations
Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,
Advertisements

Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.
Stephanie J. Lee, Loretta A. Williams 
Biology of Blood and Marrow Transplantation
Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Improvement in Hematopoiesis with Treatment of Iron Overload Following Allogeneic Transplants  Akash Mukherjee, MD, Dhaval Shah, MD, Gloria Obi, PhD,
Liver Transplantation for Hepatic Graft-Versus-Host-Disease: A United Network for Organ Sharing (UNOS) Database Study  Shahrukh Hashmi, MD MPH, Timucin.
Using A3 Methodology to Identify the Root Cause of a Chemotherapy Error in a Hematopoietic Stem Cell Transplant Patient  Kathlene DeGregory, PharmD, BCOP,
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.
Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.
Access to Hematopoietic Cell Transplantation in the United States
Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic.
Outcomes after Matched Unrelated Donor and Haploidentical Related Donor Allogeneic Transplantation for Hematological Malignancies: Single Center Experience 
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.
Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.
Stephanie J. Lee, Loretta A. Williams 
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
Pauline A. Daniels, DO, Stella M
Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease  Nelson J. Chao, MD, MBA, Yevgeniya Gora Foster, MD, Krista Rowe, RN, MSN,
More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan.
Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection  Ron Mihelic,
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Safety and Efficacy of Amiloride in Reducing the Need for Magnesium Supplementation in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Calcineurin.
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation 
Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients  Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Amlodipine and Calcineurin Inhibitor Induced Nephrotoxicity Following Allogeneic Hematopoietic Stem Cell Transplant  Ryan R. Jensen, Regan Healy, Clyde.
Members of the Intestinal Microbiota Are Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Jonathan U. Peled, MD, PhD,
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies  Ensi Voshtina,
Biology of Blood and Marrow Transplantation
Identification of Potential Barriers and Incentives for BMT Nurses to Apply for and Maintain BMTCN Certification  Brittney Nicole Browne, BSN, RN, OCN,
Cannabidiol for the Prevention of Graft-Versus-Host-Disease after Allogeneic Stem Cell Transplantation: Results of a Phase I/II Study  Moshe Yeshurun,
Infection Prevention - Visitors and the Best of Intentions
Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.
Integrative Therapy Use as a Comfort Measure with BMT Patients
Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation?  Melhem.
Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience  Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.
A Successful Approach to Decreasing Central Line Associated Blood Stream Infections  Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.
Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
The Role for Induction Chemotherapy and Allogeneic Stem Cell Transplant in Patients with Chronic Myelomonocytic Leukemia That Have Undergone Leukemic.
Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D
Gerard Socié, K. Scott Baker, Smita Bhatia 
Prediction of Severe Acute Graft-Versus-Host Disease (GVHD) in Recipients of HLA Identical Hematopoietic Cell Transplantation (HCT) Using Donor Gene Expression.
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
Does Cryopreserved Hematopoietic Stem Cell Product Need an Expiration Date? Recipients Engrafted Despite Infusion of Products over Five Years in Storage.
Biology of Blood and Marrow Transplantation
Calcinuerin-Inhibitor (CI) Free Graft-Versus-Host Disease (GvHD) Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care  Marlee Muilenburg,
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia  SungNam Lim, Je-Hwan Lee, MD, PhD,
Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation 
Close Monitoring of Cyclosporine A Concentration as a Means of Preventing Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Recipients  Marietta.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
In Memoriam: E. Donnall Thomas
The Incidence and Outcomes of Oral Mucositis Among Allogeneic Stem Cell Transplantation Patients: A Systematic Review and Meta-Analysis  Hafsa Myedah.
Presentation transcript:

Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies  Rashmi Khanal, MD, Valeriy Sedov, MD, Ridhi Gupta, MD, Mark Thomas Burbridge, DO, Colleen Butcher, BSN, RN, OCN, Kylie Capdevila, NP, Kathy Hogan Edwards, PharmD, Kristy Martin, SRA, Amanda Littleton, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Molly Schneider, BSN, RN, APHON, Juan Carlos Varela, MD, PhD, Elizabeth J. Williams, CQIA, Robert Stuart, MD, Saurabh Chhabra, MD, Carolyn Ann Gentles, MSN, FNP  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S330-S331 (March 2016) DOI: 10.1016/j.bbmt.2015.11.809 Copyright © 2016 Terms and Conditions

Biology of Blood and Marrow Transplantation 2016 22, S330-S331DOI: (10 Biology of Blood and Marrow Transplantation 2016 22, S330-S331DOI: (10.1016/j.bbmt.2015.11.809) Copyright © 2016 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.